Gilead Sciences | GILD - Capital Social e Reservas

Preço das Ações
128.84
Mudança Diária
-0.42 -0.32%
Mensal
-5.50%
Anual
20.93%
Q2 Previsão
127.61




Capital Social e Reservas Alterar Data
AbbVie USD -3.27B 628M 2025-12
Agios Pharmaceuticals USD 1.11B 84M 2026-03
ALKERMES USD 1.82B 85.86M 2025-12
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
Amgen USD 8.66B 961M 2025-12
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Coherus Biosciences USD 61.01M 26.76M 2025-12
Eli Lilly USD 26.54B 2.74B 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
GlaxoSmithKline GBP 16.38B 229M 2025-12
Glaxosmithkline GBP 22.06B 360M 2025-12
Incyte USD 5.62B 455.37M 2026-03
J&J USD 81.19B 358M 2026-03
Merck USD 51.85B 2.79B 2025-09
Moderna USD 8.65B 680M 2025-12
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Novartis USD 46.13B 1.38B 2025-12
Pfizer USD 92.8B 4.11B 2025-09
PTC Therapeutics USD -205.31M 49.56M 2025-12
Puma Biotechnology USD 115.27M 10.55M 2025-09
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 72.81B 1.1B 2026-03
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
United Therapeutics USD 7.1B 506M 2025-12
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12